$BNTX

BNTXBioNTech SE American Depositary Share

What are people saying about BioNTech SE American Depositary Share (BNTX) stock on YouTube?

In the past 7 days (As of 11-18), 1 YouTube channel discussed BioNTech SE American Depositary Share (BNTX) in 1 entry. Most recent: The Motley Fool, 2026-11-14.

All takes and content in this window

As of 11-18
11-14
The Motley FoolPublished 2026-11-14
“4 Stocks to Buy Before the End of 2026!”
$BNTXBullish
AI summary · Billion to One counts individual DNA molecules rather than estimating proportions, giving single-molecule precision for tests competitors lack. Quarterly revenue beat consensus by about 50% YoY, diluted EPS more than doubled expectations, and oncology revenue rose 96% to about a $68 million annual rate; it posted a fifth straight positive GAAP operating income. A blood-based minimal residual disease test for all solid tumors launches mid-December, expanding its tumor tests in an administration-estimated $30 billion market; the speaker sees a long growth runway and puts it on the watchlist before end-2026.

will be the most important to the company and its growth story in the future. One of the interesting things is to talk about the platform technology that Billion to One relies on.

Just to explain why it's a bit more distinctive.

The Billion to One platform works by linking a unique tag to each DNA molecule, enabling it to actually count those molecules rather than estimate their proportion. You can think of it as the difference between weighing a mixed bag of coins to estimate the number of coins in it, versus marking and counting each coin individually.

Showing 1 / 1 on this page
See this ticker’s full history